undamentalytics Newsletter
Sign in

Vivosim Labs, Inc. (VIVS) stock

Add to watchlist

Add holding +

NASDAQ: VIVS Nasdaq Biotechnology Next results ~November 12, 2026

Vivosim Labs, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Vivosim Labs, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling1 purchase and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds6 adding, 7 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Vivosim Labs files

Where Vivosim Labs stands after its latest 10-Q

Vivosim Labs has little or no product revenue yet; it used $10m of cash in the twelve months to June 2026. The diluted share count is up 83.4% on a year earlier, which dilutes existing holders. It passes 1 of our 3 financial-health checks.

Our model value for Vivosim Labs is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Vivosim Labs, Inc.'s trailing-twelve-month revenue fell 21.1% year on year, with a free-cash-flow margin of -9038.4%.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 3.0% while net income fell 520.9%: a 524pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 21.1% over the last 12 months.
  • Growth slowing. The growth rate is 12.1 points lower than a quarter earlier.
  • Loss-making. Operating margin is -10117.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 1564.1 points on a year ago.
  • Burning cash. Free cash flow was -9038.4% of revenue over the last 12 months.

Latest results: FY2027 Q1

Filed August 12, 2026
Revenue
$0m, down 51.4% on a year earlier
Share reaction
+30.6% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500

Vivosim Labs' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week0.0%
  • 1 month-25.0%
  • This year-91.7%
  • 1 year-94.4%
  • 5 years-99.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$112,000
Operating margin
-10117.0%
Net margin
-11016.1%
EPS (TTM, diluted)
$-3.77

Growth

Revenue growth
−21.1%
Change in growth rate
−12.1 pts
Share count change
+83.4%

Cash

Free cash flow (TTM)
-$10.1M
FCF margin
-9038.4%
Stock pay % of revenue
282.1%

Earnings

Last results
August 6, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Leadership
  3. Results
  4. Announcement
  5. Announcement
  6. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Vivosim Labs, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$520.80$763.20$247.20$237.60$98.40$115.68$45.12$26.28$12.36$2.24$1.43$0.15
Market value$391m$622m$221m$228m$106m$133m$65m$38m$19m$3m$4m$490840
+ Net debt (− = net cash)−$62m−$63m−$44m−$36m−$27m−$37m−$29m−$15m−$3m−$11m−$5m−$2m
Enterprise value$329m$559m$177m$192m$79m$96m$37m$23m$16m−$8m−$1m−$1m
Multiples
Price / sales n/m147.0x48.0x73.9x48.4x—43.6x103.1x172.8x22.8x28.3x4.4x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

18 /100

Weak moat

How hard Vivosim Labs's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -38.1% of total assets over 7 years.

  • Pricing power 14 / 20

    Gross margin has been a median 82.5%, moving by 8.5 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -2046.1%; its worst year was -19557.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -2240.7% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 558.7% over five years; stock-based pay has been a median 229.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Vivosim Labs, Inc.: too few analysts cover it.

Positioning

Short interest
3.6%
of tradable shares
Days to cover
0.58
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
11%
of shares
Held by insiders
2.7%
of shares
Employees
15
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −94.4%

$2.70 on October 31, 2025 to $0.15

ThenNowEffect
Revenue (last 12 months) $142000 $112000 −21.1%
P/S multiple 67.8x 7.0x −89.7%
Share count 4m 5m −31.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VIVS−71%−61%−21%−59%−67%−92%
Industry peers (median)−35%−56%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VIVS17%25%33%33%33%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VIVS−83%−68%−67%−75%−91%−95%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 100% from August 8, 2016 to October 23, 2026. Getting back needed a 769500% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.15 – $2.92
From 52-week high
−94.9%
vs 50-day average
−32.0%
vs 200-day average
−85.9%
Volatility (1 year)
122%
Beta vs S&P 500
1.77

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±12.1%
After a week
1 up, 11 down
typical move ±11.1%
After a month
2 up, 10 down
typical move ±16.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +30.6% +0.5% −8.3% −22.2%
April 2, 2025 −2.7% −4.3% −4.9% −10.3%
May 22, 2019 −43.2% −1.5% −14.7% −53.7%
February 7, 2019 +2.0% −0.8% +8.2% +8.2%
November 8, 2018 +0.9% −1.2% −3.5% −8.8%
August 9, 2018 −13.1% −0.8% −10.8% −6.2%
May 31, 2018 −24.9% +0.4% −29.5% −27.5%
February 8, 2018 −10.2% −2.3% −19.7% −14.6%
November 9, 2017 +4.8% −0.4% −1.4% −5.4%
October 4, 2017 −6.3% +0.7% −24.0% −29.0%
August 9, 2017 −1.4% −1.4% −1.0% +3.3%
June 7, 2017 −5.2% +0.2% −7.7% −5.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Vivosim Labs, Inc.
$0 $100K $200K $300K $400K FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $368K Revenue (TTM), FY24 Q3: $242K Revenue (TTM), FY24 Q4: $109K Revenue (TTM), FY25 Q1: $73K Revenue (TTM), FY25 Q2: $103K Revenue (TTM), FY25 Q3: $122K Revenue (TTM), FY25 Q4: $144K Revenue (TTM), FY26 Q1: $142K Revenue (TTM), FY26 Q2: $140K Revenue (TTM), FY26 Q3: $142K Revenue (TTM), FY26 Q4: $131K Revenue (TTM), FY27 Q1: $112K $112K

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $368K
FY24 Q3 $242K
FY24 Q4 $109K
FY25 Q1 $73K
FY25 Q2 $103K
FY25 Q3 $122K
FY25 Q4 $144K
FY26 Q1 $142K
FY26 Q2 $140K
FY26 Q3 $142K
FY26 Q4 $131K
FY27 Q1 $112K
Revenue growth, TTM YoY Vivosim Labs, Inc.
-100% -50% 0% 50% 100% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: -76.7% Revenue growth, TTM YoY, FY24 Q3: -85.8% Revenue growth, TTM YoY, FY24 Q4: -70.5% Revenue growth, TTM YoY, FY25 Q1: -83.6% Revenue growth, TTM YoY, FY25 Q2: -72.0% Revenue growth, TTM YoY, FY25 Q3: -49.6% Revenue growth, TTM YoY, FY25 Q4: 32.1% Revenue growth, TTM YoY, FY26 Q1: 94.5% Revenue growth, TTM YoY, FY26 Q2: 35.9% Revenue growth, TTM YoY, FY26 Q3: 16.4% Revenue growth, TTM YoY, FY26 Q4: -9.0% Revenue growth, TTM YoY, FY27 Q1: -21.1% -21.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 -76.7%
FY24 Q3 -85.8%
FY24 Q4 -70.5%
FY25 Q1 -83.6%
FY25 Q2 -72.0%
FY25 Q3 -49.6%
FY25 Q4 32.1%
FY26 Q1 94.5%
FY26 Q2 35.9%
FY26 Q3 16.4%
FY26 Q4 -9.0%
FY27 Q1 -21.1%
Operating margin (TTM) Vivosim Labs, Inc.
-20000% -15000% -10000% -5000% 0% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: -5284.8% Operating margin (TTM), FY24 Q3: -8169.0% Operating margin (TTM), FY24 Q4: -13840.4% Operating margin (TTM), FY25 Q1: -19557.5% Operating margin (TTM), FY25 Q2: -12398.1% Operating margin (TTM), FY25 Q3: -10293.4% Operating margin (TTM), FY25 Q4: -8761.1% Operating margin (TTM), FY26 Q1: -8552.8% Operating margin (TTM), FY26 Q2: -8694.3% Operating margin (TTM), FY26 Q3: -8066.2% Operating margin (TTM), FY26 Q4: -8768.7% Operating margin (TTM), FY27 Q1: -10117.0% -10117.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -5284.8%
FY24 Q3 -8169.0%
FY24 Q4 -13840.4%
FY25 Q1 -19557.5%
FY25 Q2 -12398.1%
FY25 Q3 -10293.4%
FY25 Q4 -8761.1%
FY26 Q1 -8552.8%
FY26 Q2 -8694.3%
FY26 Q3 -8066.2%
FY26 Q4 -8768.7%
FY27 Q1 -10117.0%
FCF margin (TTM) Vivosim Labs, Inc.
-20000% -15000% -10000% -5000% 0% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: -4478.8% FCF margin (TTM), FY24 Q3: -6991.3% FCF margin (TTM), FY24 Q4: -13481.7% FCF margin (TTM), FY25 Q1: -16920.5% FCF margin (TTM), FY25 Q2: -11486.4% FCF margin (TTM), FY25 Q3: -8286.9% FCF margin (TTM), FY25 Q4: -6579.2% FCF margin (TTM), FY26 Q1: -7345.8% FCF margin (TTM), FY26 Q2: -7252.9% FCF margin (TTM), FY26 Q3: -7481.7% FCF margin (TTM), FY26 Q4: -8264.9% FCF margin (TTM), FY27 Q1: -9038.4% -9038.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -4478.8%
FY24 Q3 -6991.3%
FY24 Q4 -13481.7%
FY25 Q1 -16920.5%
FY25 Q2 -11486.4%
FY25 Q3 -8286.9%
FY25 Q4 -6579.2%
FY26 Q1 -7345.8%
FY26 Q2 -7252.9%
FY26 Q3 -7481.7%
FY26 Q4 -8264.9%
FY27 Q1 -9038.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-KT, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2010 2012 Dec 2011 2013 Dec 2012 2014 Mar 2014 2015 Mar 2015 2016 Mar 2016 2017 Mar 2017 2018 Mar 2018 2019 Mar 2019 2020 Mar 2020 2021 Mar 2021 2022 Mar 2022 2023 Mar 2023 2024 Mar 2024 2025 Mar 2025 2026 Mar 2026 LTM Jun 2026
Income
Revenue 1 1 1 0 1 1 4 5 3 2 0 2 0 0 0 0 0
Gross profit — — — — 1 1 3 4 3 2 0 — — — 0 0 —
EBITDA −1 −2 −9 −20 −30 −38 −37 −34 −26 −20 −17 −11 −17 −15 −12 −11 −11
Operating income −1 −2 −9 −21 −30 −39 −39 −35 −27 −21 −17 −11 −18 −15 −13 −11 −11
Net income −1 −4 −44 −26 −30 −39 −38 −35 −27 −19 −17 −11 −17 −15 −2 −14 −12
Diluted EPS $0.00 $0.00 $0.00 −$2.10 −$45.60 −$51.60 −$2.34 −$38.40 −$1.38 −$16.80 −$14.64 −$7.92 −$11.88 −$9.63 −$1.70 −$5.35 −$3.77
Growth (year on year)
Revenue — +60.7% +23.5% −68.3% +50.7% +159.7% +185.2% +8.8% −32.8% −29.0% −100.0% — −75.3% −70.5% +32.1% −9.0% −21.1%
Margins
Gross margin — — — — 100.0% 100.0% 77.4% 78.3% 83.8% 86.3% — — — — 96.5% 100.0% —
EBITDA margin −185.6% −230.9% −762.2% <−999% <−999% <−999% −884.8% −738.7% −850.7% −925.9% — −755.8% <−999% <−999% <−999% <−999% <−999%
Operating margin −195.4% −237.9% −778.5% <−999% <−999% <−999% −911.9% −766.3% −882.4% −977.9% — −765.3% <−999% <−999% <−999% <−999% <−999%
Net margin −222.1% −452.3% <−999% <−999% <−999% <−999% −908.9% −756.1% −861.7% −852.0% — −763.2% <−999% <−999% <−999% <−999% <−999%
Free-cash-flow margin −143.9% −202.3% −839.6% <−999% <−999% <−999% −722.0% −631.8% −661.7% −677.7% — −590.8% <−999% <−999% <−999% <−999% <−999%
Cash flow
Cash from operations −1 −2 −10 −16 −20 −29 −29 −29 −20 −15 −13 −8 −12 −15 −9 −11 −10
Capital spending 0 0 0 0 2 2 1 0 0 0 0 0 0 0 0 0 0
Free cash flow −1 −2 −10 −16 −21 −31 −31 −29 −20 −15 −14 −9 −13 −15 −9 −11 −10
Stock-based pay 0 0 1 5 7 9 7 7 5 4 6 2 2 2 1 0 0
Free cash flow after stock pay −1 −2 −11 −20 −28 −40 −38 −36 −26 −19 −19 −11 −15 −16 −10 −11 −10
Balance sheet
Cash — — — 48 50 62 63 44 36 27 37 29 15 3 11 5 2
Total debt 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) — — — −48 −50 −62 −63 −44 −36 −27 −37 −29 −15 −3 −11 −5 −2
Diluted shares — — — — — — — — — 1m 1m 1m 1m 2m 1m 3m 3m
Returned to shareholders
Buybacks — — — — — — — — — 0 0 0 — — — — —
Total returned — — — — — — — — — 0 0 0 — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $4m
Short-term assets $3mLonger-term assets $1m
What it owes, and who funded it · $6m
Short-term liabilities $2mLonger-term liabilities $4mShareholders' equity $-2m
  • Short-term assets cover short-term liabilities $3m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $3m short-term assets against $4m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$11m against $12,000 of interest.

From Vivosim Labs, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+83.4%
year over year
R&D spending
3857.1%
of revenue
Sales & admin spending
6359.8%
of revenue
Days sales outstanding
95 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated VIVS IBIO LSTA AIM CLDX CLNN Median
Revenue, last 12 months $112000 $100000 $100000 $95000 $158000 $197000 $55m
Revenue growth, last 12 months −21.1% −75.0% −90.7% −21.5% −97.3% −31.1% 12.2%
Revenue growth, 3-year average −36.9% −62.4% — −17.3% −63.5% −36.9% 13.1%
Revenue growth, latest quarter −51.4% −100.0% −100.0% 4.0% −97.0% 233.3% 10.2%
Gross margin 100.0% 59.9% 7.7% −968.5% — 70.1% 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average <−999% <−999% <−999% <−999% <−999% <−999% −365.3%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average <−999% <−999% <−999% <−999% <−999% <−999% −313.4%
Stock pay / revenue 282.1% >999% >999% 0.0% >999% >999% 20.7%
Change in share count 83.4% 13.9% 5.1% 49.8% 4.7% 35.4% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to March 31, 2026
Products and services
Line of business Revenue Share YoY
Royalty $131,000 100.0% ▲ 10.1%
Products $0 0.0% ▼ 100.0%

From Vivosim Labs, Inc.'s 10-K filed July 14, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$109,707
Institutions reporting
24
Shares held vs prior quarter
▲ 5.3%
Positions opened / closed
4 / 3

Top buyers and sellers, Q2 2026: 6 institutions bought and 7 sold ; the biggest buyer was Renaissance Technologies LLC (+19K shares) and the biggest seller Goldman Sachs Group Inc (−16K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Geode Capital Management, LLC $27,795 26K 25.3% ▼ 29.5%
Renaissance Technologies LLC $19,795 19K 18.0% New
HRT Financial LP $19,000 18K 17.3% New
Vanguard Capital Management LLC $16,447 15K 15.0% 0.0%
Blackrock, Inc. $12,644 12K 11.5% 0.0%
Vanguard Fiduciary Trust Co $7,493 7K 6.8% 0.0%
Tower Research Capital LLC (TRC) $5,616 5K 5.1% ▲ 127.4%
Sbi Securities Co., Ltd. $236 0K 0.2% 0.0%
Larson Financial Group LLC $178 0K 0.2% 0.0%
Albion Financial Group $171 0K 0.2% 0.0%
Wells Fargo & Company $119 0K 0.1% 0.0%
Osaic Holdings, Inc. $88 0K 0.1% ▼ 11.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Vivosim Labs, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2,800 1 trade by 1 insider, last 12 months Insider sales History → $7,316 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $4,516 net selling
Insider Date Trade Shares Price Value
Lialin Tony Serge Chief Commercial Officer August 31, 2026 Buy 10,000 $0.28 $2,800
Gobel David Director November 17, 2025 Sell 3,266 $2.24 $7,316

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • April 2, 2025
  • May 22, 2019
  • February 7, 2019
  • November 8, 2018
  • August 9, 2018

Recent SEC filings

Data status

When each part of this page on Vivosim Labs, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Vivosim Labs, Inc. in brief

What does Vivosim Labs, Inc. do?
Vivosim Labs, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.
What is Vivosim Labs, Inc.'s stock ticker?
Vivosim Labs, Inc. trades under the ticker VIVS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Vivosim Labs, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Vivosim Labs, Inc. reported revenue of $112,000, 21.1% lower than a year earlier, according to its SEC filings.
What is Vivosim Labs, Inc.'s free cash flow?
Vivosim Labs, Inc.'s free-cash-flow margin is -9038.4% of revenue over the trailing twelve months.
Who are Vivosim Labs, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Geode Capital Management, LLC, Renaissance Technologies LLC and HRT Financial LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Vivosim Labs, Inc.'s market cap?
On November 2, 2026, Vivosim Labs, Inc.'s market capitalisation was about $490,840 and net debt of -$1.7M. Market figures come from third-party market data and may be delayed.
Who are Vivosim Labs, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Vivosim Labs, Inc. are Ibio, Inc., Lisata Therapeutics, Inc., AIM Immunotech Inc., Celldex Therapeutics, Inc. and Clene Inc. The side-by-side comparison below sets their revenue, margins and growth against Vivosim Labs, Inc.'s.
Are insiders buying or selling Vivosim Labs, Inc. stock?
Over the last 12 months, Vivosim Labs, Inc.'s directors and officers reported 1 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Vivosim Labs, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Vivosim Labs, Inc. announces its own schedule.